Alerta

一种负载蓝莓花色苷的果胶纳米颗粒的制备方法及其应用

Resumen de: CN121606078A

本发明属于食品科学与功能材料领域，涉及一种负载蓝莓花色苷的果胶纳米颗粒的制备方法及其应用，将蓝莓进行匀浆，超声提取，收集滤液，浓缩，冻干得到蓝莓花色苷粉末；将过滤得到的蓝莓残渣进行干燥、粉碎过筛，进行水解提取，滤液进行离心，加入乙醇，过滤收集蓝莓湿果胶，漂洗，干燥、粉碎形成蓝莓果胶；将蓝莓花色苷配成溶液，将蓝莓果胶配成溶液，将两种溶液混合，超声，离心、冻干、固化成型，得到负载蓝莓花色苷的果胶纳米颗粒。通过果胶包埋形成纳米颗粒，能显著提升花色苷在口腔、胃、肠等消化阶段的保留率。对DPPH、ABTS、羟基自由基的清除能力均有提升，有较强的抗氧化活性。有助于推动蓝莓花色苷在营养强化、医药等领域的应用。

一种纳米制剂及其制备方法和应用

Resumen de: CN121606551A

本申请涉及一种纳米制剂及其制备方法和应用，具体涉及生物医用材料技术领域。所述纳米制剂具有核壳结构，包括核心和外壳，所述核心包括光敏剂和糖代谢抑制剂，所述外壳包括两亲性聚合物，其中，所述光敏剂为近红外二区荧光染料TTQ‑BT‑TPA，所述糖代谢抑制剂包括氯尼达明，所述两亲性聚合物包括1,2‑二硬脂酰基‑sn‑甘油‑3‑磷酸乙醇胺‑聚乙二醇2000。本申请提供的纳米制剂，以解决相关技术中传统光动力疗法因依赖氧气而在肿瘤缺氧区疗效受限、肿瘤细胞因代谢重编程维持高水平抗氧化防御系统导致对铁死亡不敏感、以及现有协同治疗体系因缺乏对肿瘤代谢的精准干预且光敏剂聚集态下荧光与活性氧产率降低而导致协同效果不佳的问题。

一种芳胺类衍生物修饰的金纳米颗粒及其制备方法与应用

Resumen de: CN121606601A

本发明涉及生物医药技术领域，具体涉及一种芳胺类衍生物修饰的金纳米颗粒及其制备方法与应用。本发明提供的芳胺类衍生物修饰的金纳米颗粒能够提高非小细胞肺癌细胞内质网应激水平，还能够提高非小细胞肺癌细胞对化疗药物的敏感度，与化疗药物协同提高非小细胞肺癌细胞的死亡率。

一种siRNA及其应用

Resumen de: CN121606598A

本发明属于生物医药技术领域，提供了一种siRNA及其应用。上述siRNA能够引起THADA基因沉默，可用于制备高脂血症、脂肪性肝病、动脉粥样硬化性心血管病等脂代谢疾病的预防或治疗药物。

含醚新型可电离脂质及其用途

Resumen de: WO2026006579A1

Compounds are provided having the following structure: (I), or a pharmaceutically acceptable salt, prodrug or stereoisomer thereof, wherein Y, Q, R, Ri, R2, m, n and o are as defined herein. Use of the compounds as a component of lipid nanoparticle formulations for delivery of a therapeutic agent, compositions comprising the compounds and methods for their use and preparation are also provided. Formula (I).

RETINAL PIGMENT EPITHELIAL (RPE) CELL-DIRECTED PEROXIDASE-BASED COMPOSITIONS, METHODS, AND SYSTEMS

Resumen de: US20260061036A1

Various peroxidases are useful in treating subjects suffering from diseases associated with buildup of bisretinoids. The disclosed peroxidases may also be useful in activating prodrugs. The disclosed peroxidases may be administered as mature proteins or as coding sequences, in the form of expression vectors (as one example viral vectors) or lipid nanoparticles.

LIPID NANOPARTICLE (LNP) COMPOSITION OR FORMULATION FOR NUCLEIC ACID THERAPEUTICS

Resumen de: US20260062716A1

The present disclosure relates generally to lipid nanoparticle compositions comprising a nucleic acid, an ionizable polymer, a cationic lipid, a phospholipid, a sterol, and a PEG-lipid. Further, the present disclosure relates generally to methods of treating or preventing a disease, comprising administering to a subject in need thereof a lipid nanoparticle composition described herein.

INDOLIUM-BASED STABILIZERS OF HYDROPHOBIC DRUGS

Resumen de: US20260060936A1

A composition containing a mixture of oligomers or co-oligomers obtained by exposing an indolium-based monomer, optionally together with an additional monomer selected from dopamine, L-dopa, norepinephrine, serotonin, and a mixture thereof, to a basic buffer. The composition may further contain a hydrophobic substance such as a drug or dietary supplement, stabilized by the oligomers above.

COMPOSITIONS AND METHODS FOR TUNABLE MAGNETIC NANOPARTICLES

Resumen de: US20260061070A1

The present disclosure presents nanoparticle compositions for use in the treatment, prevention, or imaging of a disease (e.g., cancer), methods of treating, preventing, or imaging a disease in a subject in need thereof with the nanoparticle compositions, and methods of preparing the nanoparticle compositions of the disclosure. The nanoparticle compositions can include a magnetic nanoparticle ferric chloride, ferrous chloride, or a combination thereof, and a dextran coating functionalized with one or more amine groups.

PROSTATE-SPECIFIC MEMBRANE ANTIGEN TARGETED DEEP-TUMOR PENETRATION OF POLYMER NANODRUGS AND METHODS OF USE THEREOF

Resumen de: US20260061082A1

PSMA targeted metal chelate nanodrugs, methods of making these nanodrugs and methods of using them for radiodiagnosis and radiotherapy are provided.

Multi-Functional Nanoparticle System for Delivery of NAD+ Precursors, Sirtuin Activators, Senolytic Agents, and Stem Cells with pH-Responsive Release

Resumen de: US20260061071A1

Disclosed is a multi-functional nanoparticle delivery system comprising a biodegradable core of poly(lactic-co-glycolic acid) (PLGA) or calcium phosphate (CaP), encapsulating a nicotinamide adenine dinucleotide (NAD+) precursor and a sirtuin activator. Surrounding the core is a liposomal or polymeric layer containing one or more senolytic agents, and an outer layer of magnetic iron oxide nanoparticles for targeted delivery, external manipulation, and imaging. In some embodiments, the nanoparticle surface is functionalized for conjugation with autologous mesenchymal stem cells to enhance homing and regenerative potential. The system is pH-responsive, releasing its payload in acidic microenvironments typical of senescent or diseased cells, while remaining stable at physiological pH. This integrated design supports NAD+ restoration, sirtuin activation, senescent cell clearance, and tissue regeneration. Applications include treatment of age-related diseases, regenerative medicine, cardiovascular and neurodegenerative disorders, and cosmetic skin rejuvenation.

MODIFIED MESSENGER RNA COMPRISING FUNCTIONAL RNA ELEMENTS

Resumen de: US20260062697A1

The present disclosure provides messenger RNAs (mRNAs) having chemical and/or structural modifications, including RNA elements and/or modified nucleotides, which provide a desired translational regulatory activity to the mRNA.

SELENIUM-CONTAINING ANALOGUES OF PHEOMELANIN AND RELATED MATERIALS AND METHODS OF MAKING

Resumen de: US20260062555A1

In an aspect, an artificial selenomelanin material comprises: one or more selenomelanin polymers; wherein the one or more selenomelanin polymers comprise a plurality of covalently bonded selenomelanin base units; and wherein a chemical formula of each of the one or more selenomelanin base units comprises at least one selenium atom. Optionally, each selenomelanin polymer is a pheomelanin. Preferably, the chemical formula of each of the one or more selenomelanin base units comprises at least one covalent bond with each of the at least one selenium atom.

NOVEL IONIZABLE LIPIDS AND LIPID NANOPARTICLES AND METHODS OF USING THE SAME

Resumen de: US20260060926A1

Novel ionizable lipids and lipid nanoparticles that can be used in the delivery of therapeutic cargos are disclosed.

CELLULAR REPROGRAMMING TO REVERSE AGING AND PROMOTE ORGAN AND TISSUE REGENERATION

Resumen de: US20260061028A1

Provided herein are engineered nucleic acids (e.g., expression vectors, including viral vectors, such as lentiviral vectors, adenoviral vectors, AAV vectors, herpes viral vectors, and retroviral vectors) that encode OCT4; KLF4; SOX2; or any combination thereof that are useful, for example, in inducing cellular reprogramming, tissue repair, tissue regeneration, organ regeneration, reversing aging, or any combination thereof. Also provided herein are recombinant viruses (e.g., lentiviruses, alphaviruses, vaccinia viruses, adenoviruses, herpes viruses, retroviruses, or AAVs) comprising the engineered nucleic acids (e.g., engineered nucleic acids), engineered cells, compositions comprising the engineered nucleic acids, the recombinant viruses, engineered cells, engineered proteins, chemical agents that are capable of activating expression of OCT4; KLF4; SOX2; or any combination thereof, an engineered protein selected from the group consisting of OCT4; KLF4; SOX2; or any combination thereof, an antibody capable of activating expression of OCT4; KLF4; SOX2; or any combination thereof, and methods of treating a (e.g., ocular disease), preventing a disease (e.g., ocular disease), regulating (e.g., inducing or inducing and then stopping) cellular reprogramming, regulating tissue repair, regulating tissue regeneration, or any combination thereof).

ENGINEERED FLAVIVIRUS ANTIGENS AND USES THEREOF

Resumen de: WO2026050432A1

The present disclosure provides modified flavivirus polypeptides useful as antigens and polynucleotides encoding the same, and related compositions, methods of making, and methods of using. Also provided herein are enveloped virus-like particles and cells comprising all or a portion of said modified flavivirus polypeptides. In particular, these modified flavivirus polypeptides are useful for eliciting an immune response against flavivirus infection.

COMPOSITIONS FOR THE MODIFICATION OF THE HUMAN APOC3 GENE

Resumen de: WO2026050318A1

Provided herein are compositions and methods for modifying the human gene, APOC3. Such compositions and methods may result in the reduction of the protein, apolipoprotein C3 (apoC-III) when administered to a human subject. Compositions and methods provided herein may comprise a CRISPR-associated (Cas) protein or uses thereof. Compositions and methods of the present disclosure may be useful for treatment of APOC3 associated conditions, including persistent chylomicronemia, familial chylomicronemia syndrome (FCS) and severe hypertriglyceridemia (SHTG).

PH-SENSITIVE NANOPARTICLE-BASED DRUG DELIVERY SYSTEM

Resumen de: WO2026049199A1

The present invention relates to a pH-sensitive nanoparticle-based drug delivery system which can be used for cancer treatment. The drug delivery system comprises: nanoparticles comprising a drug and having a linker on the surface thereof; and a fusion protein comprising a polypeptide which binds to the linker and an antibody which specifically binds to a tumor, wherein the drug is characterized by being eluted from the nanoparticles in a tumor microenvironment, thereby making it possible to minimize side effects such as toxicity to normal tissues and maximize therapeutic effects on the tumor.

METHOD FOR OBTAINING PHOTOSENSITIVE NANOPOLYMERS TO ENCAPSULATE HYDROPHILIC AND HYDROPHOBIC MOLECULES

Resumen de: WO2026047578A1

The present invention relates to a method for synthesising a photosensitive polyethylene glycol (PEG) and methyl ether-poly(d,l-lactide) (PDLLA) polymer by tosylating its organic group. The photosensitive PEG-PDLLA polymer is functionalised by opening the Lactide monomer ring by polymerising and covalently bonding with the alcohol terminal group of PEG via an esterification with the tosylated organic group. The nanopolymer obtained using the disclosed method is suitable for controlled release processes of hydrophobic and hydrophilic active ingredients with specific delivery based on photodynamic therapy. The PEG-PDLLA-based nanopolymer obtained is able to encapsulate hydrophobic and hydrophilic active ingredients, configuring a nanocarrier with amphiphilic filler with high potential for photodynamic therapy. The method in turn involves nanoprecipitation by removing the organic solvent with optimal photo response properties to UV light.

NANOPARTICLE SYSTEM COMPRISING A METAL COATED WITH POLYETHYLENE GLYCOL (PEG) AND FUNCTIONALISED WITH A POLYPHENOL ORGANIC ACID, MANUFACTURING METHOD AND USE OF SAID SYSTEM

Resumen de: WO2026047271A1

The present invention relates to a nanoparticle system comprising a metal selected from silver and gold, coated with polyethylene glycol (PEG) and functionalised with a polyphenol organic acid selected from caffeic acid, gallic acid and ferulic acid. The present invention also relates to a method for manufacturing said nanoparticle system and to the therapeutic and cosmetic use of said nanoparticle system.

USE OF TRNA IN PROMOTING PROTEIN-CODING ABILITY OF MRNA

Resumen de: WO2026045748A1

The present invention relates to the use of tRNA in promoting the protein-coding ability of mRNA. The expression level of a target protein is improved by means of overexpressing tRNA, and a codon corresponding to the tRNA can promote or improve the stability of the mRNA. Further provided is a new tRNA+mRNA immunopotentiating vaccine. By means of introducing one or more tRNA molecules, the antigen protein encoding ability of an mRNA vaccine is enhanced, thereby eliciting stronger humoral and cellular immune responses in vivo. Further provided is a recombinant cell for producing an antibody. The recombinant cell overexpresses tRNA capable of increasing the expression level of the antibody, and the tRNA comprises a tRNA isodecoder family. Further provided is a recombinant cell for producing or packaging recombinant AAV, wherein the recombinant cell overexpresses tRNA capable of improving the AAV packaging efficiency.

POLYMERIC NANOPARTICLES FOR DIAGNOSIS AND TREATMENT OF RADIOTHERAPY-INDUCED BRAIN INJURY

Resumen de: WO2026050738A1

The present disclosure provides polymeric nanoparticles including block copolymers which possess reactive oxygen species (ROS) quenching units to reduce oxidative stress to prevent neurodegeneration and which can also be used to encapsulate an active pharmaceutical ingredient, a diagnostic marker, or a combination thereof in a pharmaceutical composition. The polymeric nanoparticles of the present disclosure are designed to release ROS quenchers, the active pharmaceutical ingredient, the diagnostic marker, or the combination thereof upon exposure to a pH below about 6.5, exposure to a reactive oxygen species, or a combination thereof. Methods of diagnosing or treating radiotherapy-induced brain injuries in a patient are also described.

COMPOSITIONS AND METHODS FOR TREATMENT OF HEPATITIS B

Resumen de: WO2026050750A1

The present invention is related to compositions and methods for modifying the hepatitis B virus (HB V) genome using CRISPR gene editing technology to treat a subject suffering from HBV. The present invention is also related to compositions of modified HB V genomes.

NUCLEAR TRANSLOCATION ENABLING SEQUENCES FOR INCREASED GENE THERAPY POTENCY

Resumen de: WO2026050148A1

Non-viral gene therapy treatments have a number of advantages over viral vectors including typical non-antigenicity, low manufacturing cost, simplicity, and efficiency of delivering genetic cargo into the cytoplasm. The potency of non-viral gene therapy systems can be enhanced by providing them with means to more efficiently transport the delivered DNA from the cytoplasm to the nucleus. Provided herein, at least in part, are means of enhancing potency of non-viral gene therapies by including novel nuclear translocation enhancing sequences and compositions that can result in optimized nuclear translocation as well as related compositions and methods.

SURFACE MODIFIED DENDRIMER FOR CONTROLLED RELEASE OF ACTIVE INGREDIENTS INTO THE SKIN

Nº publicación: WO2026050140A1 05/03/2026

Solicitante:

BOARD OF REGENTS THE UNIV OF TEXAS SYSTEM [US]
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM

Resumen de: WO2026050140A1

A modified nanoparticle nanocarrier system for delivering one or more active ingredients into a skin that can slowly release the active ingredients is provided. The modified nanoparticle nanocarrier system comprises a dendrimer, a linker and a peptide, wherein the dendrimer is first coated with the linker to form a dendrimer-linker conjugate, and the dendrimer-linker conjugate is then coupled to a peptide to form a dendrimer-linker-peptide conjugate. Subsequently, the dendrimer-linker-peptide conjugate is loaded with one or more active ingredients and mixed with a topical base to form a homogenized product to be applied onto the skin.